Video

Dr. Ravi on unmet needs in PSMA-targeted paradigm

Author(s):

Urology Times staff

Praful Ravi, MB, BChir, MRCP, discusses remaining needs and next steps with PSMA-targeted agents in prostate cancer.Ravi is a medical oncologisxt at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Related Content
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke
The level II code A9616 will be effective starting on October 1, 2025.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting
June 23rd 2025

FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting

Hannah Clarke Jason M. Broderick
The label expansion follows the FDA approval of an expanded label for 177Lu-PSMA-617 for use in patients with mCRPC after ARPI therapy and before chemotherapy.
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
June 13th 2025

64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence

Hannah Clarke
The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin.
PSMA-PET imaging product, Gozellix, launches on US market
June 11th 2025

PSMA-PET imaging product, Gozellix, launches on US market

Hannah Clarke
Gozellix was approved by the FDA in March 2025.
Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
April 8th 2025

Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

Phillip Kuo, MD, PhD Hannah Clarke
"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
© 2025 MJH Life Sciences

All rights reserved.